Antitumor activity of novel chimeric peptides derived from cyclinD/CDK4 and the protein transduction domain 4

Amino Acids

Volumn 44, Issue 2, 2013, Pages 499-510

  Wang, Haili ^a,c   Chen, Xi ^b   Chen, Yanping ^a   Sun, Lei ^a   Li, Guodong ^a   Zhai, Mingxia ^a   Zhai, Wenjie ^a   Kang, Qiaozhen ^a   Gao, Yanfeng ^a   Qi, Yuanming ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Henan Province Research Institute for Population and Family Planning   (China)

Author keywords

Antitumor; Apoptosis; CDK4; CyclinD; Peptide

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; FLUOROURACIL; PROTEIN TRANSDUCTION DOMAIN 4 D1; PROTEIN TRANSDUCTION DOMAIN 4 D3; PROTEIN TRANSDUCTION DOMAIN 4 K4; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE 4; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866562484     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-012-1360-5     Document Type: Article

References (42)

1. Andrews MJ, Kontopidis G, McInnes C, Plater A, Innes L, Cowan A, Jewsbury P, Fischer PM (2006) REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. ChemBioChem 7(12):1909-1915. doi: 10.1002/cbic.200600189
2. Caldon CE, Sutherland RL, Musgrove E (2010) Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 9(10):1918-1928 pii:11474
3. Chen W, Lee J, Cho SY, Fine HA (2004) Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 64(11):3949-3957. doi: 10.1158/0008-5472.CAN-03- 3906
4. Cooper K (2006) Rb, whi it's not just for metazoans anymore. Oncogene 25(38):5228-5232. doi: 10.1038/sj.onc.1209630
5. Day PJ, Cleasby A, Tickle IJ, O'Reilly M, Coyle JE, Holding FP, McMenamin RL, Yon J, Chopra R, Lengauer C, Jhoti H (2009) Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA 106(11):4166-4170. doi: 10.1073/pnas.0809645106
6. De Falco M, Luca De (2010) A Cell cycle as a target of antineoplastic drugs. Curr Pharm Des 16(12):1417-1426 pii:BSP/CPD/E-Pub/00043
7. Echalier A, Endicott JA, Noble ME (2010) Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta 1804(3):511-519. doi: 10.1016/j.bbapap.2009.10.002
8. Eiriksdottir E, Konate K, Langel U, Divita G, Deshayes S (2010) Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta 1798(6):1119-1128. doi: 10.1016/j.bbamem.2010. 03.005
9. Emmerich J, Meyer CA, de la Cruz AF, Edgar BA, Lehner CF (2004) Cyclin D does not provide essential Cdk4-independent functions in Drosophila. Genetics 168(2):867-875. doi: 10.1534/genetics.104.027417
10. Gerard C, Goldbeter A (2009) Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. Proc Natl Acad Sci USA 106(51):21643-21648. doi: 10.1073/pnas.0903827106
11. Gondeau C, Gerbal-Chaloin S, Bello P, Aldrian-Herrada G, Morris MC, Divita G (2005) Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J Biol Chem 280(14):13793-13800. doi: 10.1074/jbc.M413690200
12. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F, Divita G (2006) A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 1758(3):384-393. doi: 10.1016/j.bbamem.2006.02.006
13. Guo CP, Liu KW, Luo HB, Chen HB, Zheng Y, Sun SN, Zhang Q, Huang L (2011) Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway. PLoS One 6(3):e17734. doi: 10.1371/journal.pone.0017734
14. Hidema S, Tonomura Y, Date S, Nishimori K (2012) Effects of protein transduction with intact myogenic transcription factors tagged with HIV-1 Tat-PTD (T-PTD) on myogenic differentiation of mouse primary cells. J Biosci Bioeng. doi: 10.1016/j.jbiosc.2011.08.025
15. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF (2001) Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61(2):474-477
16. Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N, Fukasawa K, Takaki T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Hayama T, Nishimura S, Morishima H (2001) A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem 44(26):4628-4640 pii:jm010326y
17. Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B (2011) Antitumor activities of recombinant human interferon (IFN)-lambda1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett 311(2):141-151. doi: 10.1016/j.canlet. 2011.07.004
18. Kudo Y, Kitajima S, Ogawa I, Miyauchi M, Takata T (2005) Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma. Oral Oncol 41(2):105-116. doi: 10.1016/j.oraloncology.2004.05.003
19. Lange CA, Yee Killing D (2011) The second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 18(4):C19-C24. doi: 10.1530/ERC-11-0112
20. Liu N, Fang H, Li Y, Xu W (2009) Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment. Curr Med Chem 16(36):4869-4888 pii:CMC-AbsEpub-092
21. Liu S, Bolger JK, Kirkland LO, Premnath PN, McInnes C (2010) Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol 5(12):1169-1182. doi: 10.1021/cb1001262
22. Lou H, Gao Y, Zhai M, Qi Y, Chen L, Lv H, Yu J, Li Y (2008) A novel peptide from alpha5 helix of Asterina pectinifera cyclin B conjugated to HIV-Tat(49-57) with cytotoxic and apoptotic effects against human cancer cells. Bioorg Med Chem Lett 18(16):4633-4637. doi: 10.1016/j.bmcl.2008.07.017
23. McInnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM (2003) Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents 3(1):57-69
24. Moeller SJ, Sheaff RJ (2006) G1 phase: components, conundrums, context. Results Probl Cell Differ 42:1-29
25. Park JS, Kim HS, Park HM, Kim CH, Kim TG (2010) Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model. Vaccine 29(47):8642-8648. doi: 10.1016/j.vaccine.2011.09.052
26. Quintanilla-Martinez L, Davies-Hill T, Fend F, Calzada-Wack J, Sorbara L, Campo E, Jaffe ES, Raffeld M (2003) Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 101(8):3181-3187. doi: 10.1182/blood-2002-01-0263
27. Rekdal O, Haug BE, Kalaaji M, Hunter HN, Lindin I, Israelsson I, Solstad T, Yang N, Brandl M, Mantzilas D, Vogel HJ (2012) The relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determines their cytotoxicity. J Biol Chem. doi: 10.1074/jbc.M111.279281
28. Reynaud EG, Guillier M, Leibovitch MP, Leibovitch SA (2000) Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity. Oncogene 19(9):1147-1152. doi: 10.1038/sj.onc.1203403
29. Roy Choudhury S, Karmakar S, Banik NL, Ray SK (2011) Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells. Neurochem Res 36(12):2292-2305. doi: 10.1007/s11064-011-0554-7
30. Sawai H, Domae N (2011) Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun 411(3):569-573. doi: 10.1016/j.bbrc.2011.06. 186
31. Shang W, Qiao J, Gu C, Yin W, Du J, Wang W, Zhu M, Han M, Lu W (2011) Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil. BMC Complement Altern Med 11(1):123. doi: 10.1186/1472-6882-11-123
32. Singh RK, Lange TS, Kim KK, Brard L (2011) A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells. Invest New Drugs 29(1):63-72. doi: 10.1007/s10637-009-9335-4
33. Strasberg Rieber M, Welch DR, Miele ME, Rieber M (1996) p53-independent increase in p21WAF1 and reciprocal down-regulation of cyclin A and proliferating cell nuclear antigen in bromodeoxyuridine-mediated growth arrest of human melanoma cells. Cell Growth Differ 7(2):197-202
34. Suojanen J, Vilen ST, Nyberg P, Heikkila P, Penate-Medina O, Saris PE, Hagstrom J, Ranta TM, Salo T, Sorsa T, Reunanen J (2011) Selective gelatinase inhibitor Peptide is effective in targeting tongue carcinoma cell tumors in vivo. Anticancer Res 31(11):3659-3664 pii:31/11/3659
35. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5(1):27-36 pii:S1470204503013214
36. Takaki T, Echalier A, Brown NR, Hunt T, Endicott JA, Noble ME (2009) The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci USA 106(11):4171-4176. doi: 10.1073/pnas.0809674106
37. Thapa N, Kim S, So IS, Lee BH, Kwon IC, Choi K, Kim IS (2008) Discovery of a phosphatidylserine-recognizing peptide and its utility in molecular imaging of tumour apoptosis. J Cell Mol Med 12(5A):1649-1660. doi: 10.1111/j.1582-4934. 2008.00305
38. Toogood PL (2001) Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 21(6):487-498. doi: 10.1002/med.1021
39. Xie SQ, Wang JH, Ma HX, Cheng PF, Zhao J, Wang CJ (2009) Polyamine transporter recognization and antitumor effects of anthracenymethyl homospermidine. Toxicology 263(2-3):127-133. doi: 10.1016/j.tox.2009.07.001
40. Yamaguchi N, Kiick KL (2005) Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 6(4):1921-1930. doi: 10.1021/bm050003
41. Yamaguchi N, Chae BS, Zhang L, Kiick KL, Furst EM (2005) Rheological characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels. Biomacromolecules 6(4):1931-1940. doi: 10.1021/bm0500042
42. Yuan F, Qin X, Zhou D, Xiang QY, Wang MT, Zhang ZR, Huang Y (2008) In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates. Eur J Pharm Biopharm 70(3):770-776. doi: 10.1016/j.ejpb.2008.06.028